KaSP is a multimodal observational study with the goal of clarifying underlying mechanisms that cause psychotic disorders, such as schizophrenia. Participants with psychotic symptoms are recruited early after first contact with health care, within 4 weeks of starting anti-psychotic medication, and are compared to controls without psychiatric diagnoses on several measures.
KaSP aims to recruit 120 patients sparsely medicated or drug-naive first episode psychosis (FEP) individuals, along with 80 healthy controls. Participants undergo the following assessments and measurements: * Clinical assessment * Cognitive testing * Lab results from cerebrospinal fluid, blood, urine, saliva and skin biopsy * Brain imaging using Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) * Pre-Pulse Inhibition (PPI) (a test to evaluate the startle response) * Measures of arterial stiffness and amount of vascular narrowing Participants with psychosis are invited back for repeat measurements at 1,5 and 5 years after study enrollment. Controls may be invited back at 1,5 years for repeat of some of the assessments.
Study Type
OBSERVATIONAL
Enrollment
200
SLSO Psykiatri Stockholm in collaboration w Karolinska Institutet
Stockholm, Sweden
RECRUITINGKynurenic acid (KYNA) in FEP compared to HC
KYNA are measured in CSF and blood samples
Time frame: Baseline measure
Cytokines in FEP compared to HC
Cytokines are measured in CSF and blood samples
Time frame: Baseline measure
Microglial activation in FEP compared to HC
Group comparison of binding of the PET ligand \[11C\]PBR-28
Time frame: Baseline measure
Dopamine receptors in FEP compared to HC
Group comparison of binding of the PET-ligand \[11C\]FLB457
Time frame: Baseline measure
Infectious risk factors in FEP and subsequent relation to clinical outcome
Registry data on previous infections, along with infectious agents measured in CSF and blood. Long term clinical outcome is measured through registry data, by drug-dispensation as well as in-and outpatient care for both somatic and psychiatric disorders.
Time frame: Registry data in childhood, measurement at baseline, registry data through study completion (with an expected average of 7 years of follow up)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.